the relapse-free survival (RFS) time of small rectal GISTs
was significantly different than that in other anatomic sites.
Study at our institute of Armed Forces Institute of Rawalpindi diagnosed 46 gastric GIST
for each gastric schwannoma.
CE-EUS has been recently used for assessment of tumor vascularity in order to predict the preoperative malignancy risk of GISTs
through identification of irregular vessels.
In 1998, Hirota et al (6) reported that most GISTs
harbored activating c-kit mutations and also showed positivity with ckit (CD117) immunohistochemistry.
Most of the GISTs
are submucosal lesions and 15 % may be exogastric as in our case, and less than 5 % can be both extra-and intraluminals (Dumbbell).
were discovered incidentally in 18 patients during diagnostic imaging studies or surgeries performed for other reasons.
arising from the outside of the alimentary tract are grouped into extragastrointestinal stromal tumors (EGISTs), and prostate is a rare presentation site.
Kindblom and associates5 reported in 1998, the actual cell of origin of GISTs
is a pluripotential mesenchymal stem cell programmed to differentiate into the interstitial cell of Cajal.
The prognosis of LMS cannot be histologically predicted and, on the basis of the relatively small series, may be better than that in patients with GISTs
with similarly high mitotic counts.
About 5% of GI hemorrhages are ambiguous in nature, with GISTs
being one of the cause.
About 80-90% of GISTs
show immunohistochemical staining for CD117 (c-KIT) and most of them contain activating mutations in the KIT receptor tyrosine kinase.
11) Tumor Parameters Percent of patients with progressive disease during long- term follow-up and characterization of risk for metastasis Group Tumor_Size_ Mitotic_Rate Gastric GISTs
1 [less than or [less than or equal 0% equal to]2 cm to]5-/-50-HPFs none 2 >2 cm [less than [less than or equal 1.
can arise from all parts of the gastrointestinal tract--stomach (50-60%), small intestine (30-40%), colon/rectum (5-10%) and esophagus (5%) (Stamatakos, Douzinas, Stefanaki, Safioleas et al.
The discovery of oncogenic KIT kinase mutations in GISTs
and the introduction of kinase inhibitor therapies have led to a rapid evolution in the understanding of these tumors.
We present a case of recurrent gastrointestinal (GI) bleeding from multiple GISTs
in a patient with NF1.